Form 4: Decheng Capital Sells BeyondSpring Shares

Decheng Capital, a 10% owner and director of BeyondSpring Inc., reported selling 13,876 ordinary shares in early October 2025.

Summary

• Decheng Capital China Life Sciences USD Fund III, L.P., a 10% owner and director of BeyondSpring Inc. (BYSI), reported sales of ordinary shares.
• On October 8, 2025, 7,507 shares were sold at a weighted average price of $1.77 per share, with prices ranging from $1.74 to $1.805.
• On October 9, 2025, 3,979 shares were sold at a weighted average price of $1.81 per share, with prices ranging from $1.79 to $1.84.
• On October 10, 2025, 2,390 shares were sold at a weighted average price of $1.77 per share, with prices ranging from $1.73 to $1.83.
• Following these transactions, Decheng Capital China Life Sciences USD Fund III, L.P. beneficially owns 1,804,020 ordinary shares.
• Additional indirect holdings include 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II, L.P. and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP.
• Dr. Xiangmin Cui is the manager of the general partners for these funds and may be deemed to beneficially own the securities, disclaiming ownership except for his proportionate pecuniary interest therein.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a 10% owner and director. This action typically signals a lack of confidence or a belief that the stock is fully valued, which can weigh on investor sentiment.

Negatives

• A significant shareholder and director, Decheng Capital, sold a total of 13,876 ordinary shares of BeyondSpring Inc.
• The sales occurred over three consecutive days, indicating a deliberate reduction in holdings.
• Insider selling can be perceived negatively by the market, suggesting a lack of confidence in the company's near-term prospects.

Risks

• Negative market perception due to insider selling by a 10% owner and director.
• Potential for increased selling pressure on BeyondSpring Inc.'s stock.
• Loss of investor confidence if other major shareholders or insiders follow suit.

Future Outlook

This Form 4 filing reports past transactions and does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

Industry Context

This filing pertains to an insider transaction and does not provide information directly related to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sector. However, significant insider selling by a major institutional investor and director could be interpreted by the market as a signal regarding the company's specific prospects within its industry.

Comparison to Industry Standards

• This filing reports an insider transaction and does not contain information that allows for a direct comparison of company results to global industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: May experience negative sentiment and potential downward pressure on the stock price due to the insider selling.
• Management: The sales by a director and significant shareholder could raise questions about management's confidence in the company's outlook.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for BeyondSpring Inc. related to these transactions.

Key Dates

Recommendation

The sale of shares by Decheng Capital, a 10% owner and director, signals a lack of confidence from a key insider. While the number of shares sold is not massive in absolute terms, the fact that a director and major institutional investor is reducing their stake suggests potential concerns about the company's valuation or future performance. This insider selling activity warrants a 'sell' recommendation for investors, as it indicates a potential negative outlook from those with privileged information.

Keywords

BeyondSpring Inc., BYSI, Decheng Capital, insider selling, Form 4, share disposition, director, 10% owner, equity sales, institutional investor